Short answer
PRECIGEN, INC. (PGEN) filed its Q1 2026 10-Q quarterly report on May 13, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $23M with net income of −$8M.
Q1 2026 key financials · XBRL
- Revenue
- $23M
- Net income
- −$8M
- +85.4% YoY
- Operating margin
- -25.8%
- EPS (diluted)
- −$0.02
- +88.9% YoY
Source: XBRL data from the PRECIGEN, INC. (PGEN) Q1 2026 10-Q on SEC EDGAR. USD.
PRECIGEN, INC. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $23.252M, up >200% YoY from $1.341M, driven by Papzimeos product revenue of $21.828M
- Product revenue $21.828M vs $203K YoY; service revenue $1.424M vs $1.138M
- Operating loss $5.994M vs $22.596M; net loss $7.929M vs $54.153M
- R&D expense $5.638M, down 46.2% YoY; SG&A $21.049M, up 70.3% on commercialization
- Pre-launch inventory estimated at $63M; gross margins expected to stabilize between high 80% and low 90%
Risk Factors
- Risk factors unchanged from the Annual Report; no new quarterly risk factor disclosed
- Insider trading-plan activity: 1,013,861 aggregate shares covered by officer and director arrangements
- CEO plan amended to increase covered shares to 477,260, with sales eligibility beginning June 29, 2026
- Trading arrangements pre-cleared under Precigen’s Insider Trading Policy
- No specific regulatory, legal, operational, competitive, liquidity, debt, currency, or concentration changes disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PRECIGEN, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.